RxDoctor Payments DataLook up a doctor →

Amanda Robinson, MD

Family Medicine · Fairhope, ALNPI 1174880546

Payments from drug & device makers

$16,837in general payments, 2019–2025

Across 708 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$788
  • Amgen$588
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$720%
  • Food & beverage$16,51698%
  • Education$390%
  • Gifts$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca53$2,311
AbbVie(2 entities)116$2,126
Novo Nordisk119$1,731
Lilly USA, LLC46$1,034
Johnson & Johnson45$788
Amgen20$588
Bayer16$558
Pfizer31$516
Merck31$455
GSK15$445
Phathom Pharmaceuticals, Inc.10$395
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$360
Genentech USA, Inc.3$347
Takeda Pharmaceuticals U.S.A., Inc.14$337
Boehringer Ingelheim18$289
Otsuka America Pharmaceutical, Inc.6$285
Hikma Pharmaceuticals USA9$268
Paratek Pharmaceuticals, Inc.3$249
Corcept Therapeutics8$246
Novartis16$231
Amarin Pharma, Inc.9$223
Sanofi-aventis U.S. LLC3$216
Corium, LLC6$213
Lundbeck LLC4$206
Biohaven Pharmaceuticals, Inc.6$196
Ironshore Pharmaceuticals Inc.6$183
Tris Pharma Inc4$169
Madrigal Pharmaceuticals1$148
Sanofi2$148
Exact Sciences2$136
Biohaven Pharmaceutical Holding Company Ltd.7$126
Jazz Pharmaceuticals Inc.1$123
Teva Pharmaceuticals USA, Inc.7$116
Impel Pharmaceuticals Inc.2$84
Antares Pharma, Inc.4$72
Supernus Pharmaceuticals, Inc.4$62
Optinose US, Inc.2$59
Shire North American Group Inc4$54
Neos Therapeutics, LP3$54
Idorsia Pharmaceuticals US Inc3$52
Upsher-smith Laboratories LLC2$47
Astellas Pharma US Inc2$46
Eisai Inc.2$43
Currax Pharmaceuticals LLC3$41
Axsome Therapeutics, Inc.2$41
Abbott2$40
Sanofi Pasteur Inc.2$34
Mylan Specialty L.p.2$33
Esperion Therapeutics, Inc.2$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$27
Avanir Pharmaceuticals, Inc.1$24
Boston Scientific1$24
Daiichi Sankyo Inc.1$23
Mallinckrodt Hospital Products Inc.1$20
Alnylam Pharmaceuticals Inc.1$20
Xeris Pharmaceuticals, Inc.1$20
Medtronic1$18
Sumitomo Pharma America, Inc.1$16
Ironwood Pharmaceuticals, Inc1$16
Halozyme Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,837 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$76,699
Medicare patients
185
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$71,895
EliquisApixaban39$46,385
Tresiba Flextouch U-200Insulin Degludec37$32,703
MounjaroTirzepatide27$31,762
JardianceEmpagliflozin21$20,400
JanuviaSitagliptin Phosphate16$12,408
Tresiba Flextouch U-100Insulin Degludec14$6,921
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,085
Omeprazole206$4,504
TegretolCarbamazepine13$3,152
Novolog FlexpenInsulin Aspart13$2,998
Gabapentin138$2,894
Atorvastatin Calcium291$2,852
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,829
Levothyroxine Sodium230$2,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,731$71,89561 claims
PfizerEliquis$516$46,38539 claims
Lilly USA, LLCMounjaro$1,034$31,76227 claims
Boehringer IngelheimJardiance$289$20,40021 claims
MerckJanuvia$455$12,40816 claims
GSKAnoro Ellipta$445$5,08511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →